CD8A and hepatocellular carcinoma: The significantly higher expression levels of MAGE-A versus NY-ESO-1 [8, 28] that have been reported not only in HCC but also in different tumors further support its better immunogenic potential and also fits to our finding with dominant MAGE-A-specific CD8+ T-cell responses.